GrayBella Capital
GrayBella Capital is a venture capital firm established in 2019, with its headquarters in Bilbao, Spain and additional offices in several major cities, including London and Boston. The firm specializes in making equity investments in seed, startup, and Series A and B stages, primarily targeting the life sciences and complex technologies sectors. Within life sciences, GrayBella focuses on areas such as diagnostics, healthcare IT, artificial intelligence, data analytics, and patient monitoring. In the realm of complex technologies, the firm's interests include IoT, cloud and SaaS platforms, security, space technology, machine learning, and fintech. GrayBella Capital typically invests between €3 million and €8 million in companies located in the United Kingdom, Ireland, Spain, Portugal, and regions such as the Nordics, Baltics, and Central and Eastern Europe. The firm actively leads or co-leads funding rounds, maintains board positions in its portfolio companies, and seeks early exit opportunities through strategic liquidity options.
ATAI Life Sciences AG is a clinical-stage biopharmaceutical company headquartered in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative treatments for mental health disorders, addressing significant unmet medical needs. ATAI employs a decentralized, technology-driven platform model to accelerate the development of therapies. Its diverse portfolio includes product candidates such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and GRX-917 (Deuterated etifoxine), among others. By pooling expertise and resources, ATAI aims to create impactful, evidence-based therapies that can transform mental health treatment. The company operates primarily in Germany and the United States.
CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.
Omnio, Inc. is a financial services provider that caters to banks, credit unions, airlines, and retailers with a range of digital solutions. Founded in 2018 and headquartered in London, the company specializes in banking-as-a-service offerings, including digital banking, managed services, digital payments, and application solutions. Notably, Omnio incorporates Domec's loyalty platform and Sercle, a prominent credit union platform in the UK that supports over 130 small financial institutions. The company's cloud-based digital platform enables businesses to deliver reliable banking and payment services tailored to meet the evolving needs of their customers. With a presence in Europe, Australia, North America, and Africa, Omnio collaborates with various global enterprises and government organizations to provide innovative financial products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.